Riociguat - Analysis and Forecasts from 2013 to 2020

Summary

GlobalData’s pharmaceuticals report, “Riociguat - Analysis and Forecasts from 2013 to 2020” provides Riociguat sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Pulmonary Arterial Hypertension market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Riociguat including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Riociguat including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2013-2020 for Riociguat in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table Of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Pulmonary Arterial Hypertension 4
2.2 Epidemiology 4
2.2.1 Prevalence 4
2.2.2 Mortality 5
2.3 Etiology 5
2.3.1 Scleroderma 5
2.3.2 Sickle Cell Disease 5
2.3.3 HIV/AIDS 5
2.3.4 Drug Abuse and Toxins 5
2.4 Economic Impact of PAH 5
2.5 GlobalData Report Guidance 6
3 Pulmonary Arterial Hypertension (PAH): Market Characterization 7
3.1 PAH Market 7
3.2 PAH Market Forecasts and CAGR 8
3.3 PAH Market : Drivers and Restraints 8
3.3.1 Drivers 9
3.3.2 Barriers 10
4 Classification of PAH 11
4.1 Classification Based on Cause and Clinical Presentation 11
4.1.1 Idiopathic PAH 11
4.1.2 Familial PAH 11
4.1.3 Drug Induced PAH 11
4.1.4 PAH Associated with Other Conditions 11
4.1.5 PAH Associated with Significant Venous or Capillary Involvement 11
4.2 Symptomatic Profile of PAH 11
5 Evolution of PAH Treatments 12
6 Medications 13
6.1 Prostanoids 13
6.1.1 Epoprostenol 13
6.1.2 Treprostinil 13
6.1.3 Iloprost 13
6.1.4 Beraprost 13
6.2 Endothelin Receptor Antagonists 13
6.2.1 Bosentan 13
6.2.2 Ambrisentan 14
6.2.3 Sitaxsentan 14
6.3 Phosphodiesterase Type 5 Inhibitors 14
6.3.1 Sildenafil 14
6.3.2 Tadalafil 14
6.4 Surgical Treatments 14
6.5 Investigational Combination Regimens 15
6.6 New Targets for PAH Therapy 15
7 Market Share by Class in PAH 17
8 Riociguat 18
8.1 Introduction 18
8.2 Mechanism of Action 18
8.3 Clinical Studies 18
9.3.1 Phase II Clinical Trial 18
9.3.2 Phase III Clinical Trial 19
8.4 Factors Affecting Sales of Riociguat 19
9.4.1 New Class of Therapeutics 19
9.4.2 Intense Competition 19
9.4.3 Safety and Efficacy 19
8.5 Drug Evaluation 20
8.5.1 Drug Risk Benefit Score 20
8.5.2 Intensity of Competition 20
8.6 Sales Forecasts 21
8.6.1 Target Patient Pool of Riociguat 21
8.6.2 Dosing 21
8.6.3 Market Penetration 21
8.6.4 Annual Cost of Therapy 22
8.6.5 Sales Projections of Riociguat 23
9 PAH Market: Appendix 32
9.1 Market Definitions 32
9.2 List of Abberiviations 32
9.3 Research Methodology 33
9.3.1 Coverage 33
9.3.2 Secondary Research 33
9.3.3 Forecasting 33
9.3.4 Number of Patients Approved to take the Drug 34
9.3.5 Net Penetration of Drug 34
9.3.6 Net Annual Dosing 35
9.3.7 Annual Cost of Therapy 35
9.3.8 Primary Research 35
9.3.9 Expert Panels 35
9.4 Drug Sales Estimates Model 36
9.5 Contact Us 36
9.6 Disclaimer 36
9.7 Sources 36

1.1 List of Tables

Table 1: PAH, Global, Major Marketed Drugs 7
Table 2: PAH, Global, Pipeline (PhaseIII) 8
Table 3: PAH Drugs Evolution 12
Table 4: Riociguat Phase II Results 18
Table 5: Drug Risk Benefit Score of Riociguat 20
Table 6: Riociguat, Estimated Annual Treatment Costs for PAH, Global, 2013 22
Table 7: Riociguat, PAH, Global, Sales Forecasts ($m), 2013-2020 23
Table 8: Riociguat, PAH, The US, Sales Forecasts ($m), 2013-2020 24
Table 9: Riociguat, PAH, The UK, Sales Forecasts ($m), 2013-2020 25
Table 10: Riociguat, PAH, France, Sales Forecasts ($m), 2013-2020 26
Table 11: Riociguat, PAH, Germany, Sales Forecasts ($m), 2013-2020 27
Table 12: Riociguat, PAH, Italy, Sales Forecasts ($m), 2013-2020 28
Table 13: Riociguat, PAH, Spain, Sales Forecasts ($m), 2013-2020 29
Table 14: Riociguat, PAH, Japan, Sales Forecasts ($m), 2013-2020 30

1.2 List of Figures

Figure 1: PAH, Global, Market Size Forecasts ($bn), 2010-2020 8
Figure 2: PAH, Worldwide, Market Share by Class (%), 2010 17
Figure 3: Drug Model Diagram of Riociguat 21
Figure 4: Riociguat, PAH, Global, Sales Forecasts ($m), 2013-2020 23
Figure 5: Riociguat, PAH, The US, Sales Forecasts ($m), 2013-2020 24
Figure 6: Riociguat, PAH, The UK, Sales Forecasts ($m), 2013-2020 25
Figure 7: Riociguat, PAH, France, Sales Forecasts ($m), 2013-2020 26
Figure 8: Riociguat, PAH, Germany, Sales Forecasts ($m), 2013-2020 27
Figure 9: Riociguat, PAH, Italy, Sales Forecasts ($m), 2013-2020 28
Figure 10: Riociguat, PAH, Spain, Sales Forecasts ($m), 2013-2020 29
Figure 11: Riociguat, PAH, Japan, Sales Forecasts ($m), 2013-2020 30
Figure 12: Riociguat, PAH, Global, Sales Distribution by Country (%), 2020 31
Figure 13: Drug Model Diagram 34
Figure 14: Patients Approved for the Drug 35

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected ...

Antibiotics: Technologies and Global Markets

Antibiotics: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Identify the major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets. - Learn about developments ...

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.